Hormone therapy for prostate cancer does not appear to increase cardiac deaths

Treating prostate cancer patients with drugs that block hormonal activity does not appear to increase the risk of death from cardiovascular disease, according to a study led by Harvard Medical School researchers at Massachusetts General Hospital.  While a 2006 report from members of the same study team found that treatment with gonadotropin-releasing hormone (GnRH) agonists increased the risk of diabetes and heart disease, the current study is the first to examine whether treatment actually increased heart-disease-related deaths.  In their Journal of Clinical Oncology report, which has been released online, the researchers note that read more

Read the whole article on Harvard Science

More from Harvard Science